Please use this identifier to cite or link to this item:
Title: Differential effects of a novel non-peptide endothelin receptor antagonist (bosentan) in rat liver and vasculature.
Austin Authors: Phillips, P A;Risvanis, John;Aldred, K L;Burrell, Louise M ;Bartholomeusz, B
Affiliation: Department of Medicine, University of Melbourne, Austin Hospital, Heidelberg, Victoria, Australia
Issue Date: 1-Dec-1995
Publication information: Clinical Science 1995; 89(6): 575-9
Abstract: 1. We studied the effects of the non-selective, non-peptide, orally active endothelin (ET) receptor antagonist bosentan (Ro 47-0203) on rat hepatic and mesenteric vascular membrane 125I-ET-1 binding characteristics in vitro and ex vivo (after bosentan by gavage in vivo). 2. Bosentan caused a concentration-dependent competitive inhibition of 125I-ET-1 binding to female rat mesenteric vascular (predominantly ETA receptors) and hepatic (predominantly ETB receptors) membranes in vitro and ex vivo. 3. The time course of the inhibition of binding ex vivo after administration of bosentan in vivo was 1-4h for mesenteric vascular (predominantly ETA receptors) binding and 1-16h for hepatic (predominantly ETB receptors) binding. 4. The time course of displacement of 125I-ET-1 binding from mesenteric vascular and hepatic membranes by bosentan in vitro was similar. 5. Since bosentan is significantly excreted by the liver, the prolonged hepatic 125I-ET-1 binding by bosentan presumably represents hepatic accumulation of bosentan, which may have implications for bosentan antagonizing the actions of ET in the liver.
Gov't Doc #: 8549075
Journal: Clinical Science
Type: Journal Article
Subjects: Animals
Endothelin Receptor Antagonists
Liver.blood supply
Mesenteric Arteries.chemistry.drug effects
Mesenteric Veins.chemistry.drug effects
Rats, Inbred WKY
Receptors, Endothelin.metabolism
Appears in Collections:Journal articles

Show full item record

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.